
Hadasit & IBM set up digital health accelerator at Hadassah Ein Kerem, Jerusalem
Hadassah Medical Center in Jerusalem and IBM Israel have announced the establishment of a special accelerator for startups in which the startups can develop advanced

Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update
Completed enrollment in pivotal Phase 3 ACCORDANCE trial is on track for topline data in mid-2019 JERUSALEM, Nov. 9, 2018 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the

Positive results in Entera Bio’s pharmacokinetic (PK) & pharmacodynamic (PD) study in patients with hypoparathyroidism
Entera Bio Ltd. (Nasdaq: ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in

The New Scientist Reports on Biondvax’s Universal Flu Vaccine
For decades, scientists have been trying to develop a universal vaccine that would protect people against seasonal flu for years, and also against pandemics, which

Anchiano Therapeutics files for $30-40m Nasdaq offering
Jerusalem based cancer treatment company Anchiano Therapeutics (TASE: ANCN), formerly BioCancell Therapeutics, has announced the publication of a confidential prospectus for an offering on Nasdaq. It is

Results of Zion Medical’s First Human Clinical Trial of HIV drug Gammora Offers Potential Cure
Zion Medical, an Israeli biotech company developing HIV and cancer treatments, has announced the results of the first clinical trial of HIV-drug Gammora, eliminating up

Hebrew U Researchers Develop Technology for 3-D Printing of Drugs
Researchers from Jerusalem’s Hebrew University unveiled their novel technology for three-dimensional printing of drug capsules on Wednesday, enabling the customization and personalization of medications unavailable

JLM-based Gamida Cell to raise $69m in Nasdaq IPO/adds Robert Blum as new Chairman of the Board
Jerusalem stem cell cancer therapy developer Gamida Cell Ltd. has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC)

CDC sponsored study: Argaman Technologies reduced by 25% hospital acquired infections and by 40% Multi-Drug Resistant Organisms in Wards!
The University of Pennsylvania Medical School Hospital is to announce the results of a study on the impact of Argaman Technologies in a hospital at the